CN106132435B - 筛选通过促进rip3表达增强抗癌药物的敏感性的抗癌辅剂的方法和试剂盒 - Google Patents
筛选通过促进rip3表达增强抗癌药物的敏感性的抗癌辅剂的方法和试剂盒 Download PDFInfo
- Publication number
- CN106132435B CN106132435B CN201480077473.XA CN201480077473A CN106132435B CN 106132435 B CN106132435 B CN 106132435B CN 201480077473 A CN201480077473 A CN 201480077473A CN 106132435 B CN106132435 B CN 106132435B
- Authority
- CN
- China
- Prior art keywords
- rip3
- expression
- cancer
- anticancer
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
Description
Claims (5)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2014-0014243 | 2014-02-07 | ||
KR20140014243 | 2014-02-07 | ||
KR10-2014-0014242 | 2014-02-07 | ||
KR20140014242 | 2014-02-07 | ||
KR1020140164963A KR101721407B1 (ko) | 2014-02-07 | 2014-11-25 | Rip3 발현을 촉진하여 항암제 감수성을 증진시키는 항암 보조제 스크리닝 방법 및 항암제 감수성 모니터링 방법 |
KR10-2014-0164963 | 2014-11-25 | ||
PCT/KR2014/011376 WO2015119362A1 (ko) | 2014-02-07 | 2014-11-25 | Rip3 발현촉진제를 유효성분으로 포함하는 항암보조용 조성물, rip3 발현을 촉진하여 항암제 감수성을 증진시키는 항암 보조제 스크리닝 방법 및 항암제 감수성 모니터링 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106132435A CN106132435A (zh) | 2016-11-16 |
CN106132435B true CN106132435B (zh) | 2021-08-27 |
Family
ID=56684818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480077473.XA Active CN106132435B (zh) | 2014-02-07 | 2014-11-25 | 筛选通过促进rip3表达增强抗癌药物的敏感性的抗癌辅剂的方法和试剂盒 |
Country Status (14)
Country | Link |
---|---|
US (1) | US10391115B2 (zh) |
EP (1) | EP3103475B1 (zh) |
JP (1) | JP6464436B2 (zh) |
CN (1) | CN106132435B (zh) |
AU (1) | AU2014382143B2 (zh) |
CA (1) | CA2938821A1 (zh) |
CL (1) | CL2016001965A1 (zh) |
HK (1) | HK1225960A1 (zh) |
IL (1) | IL247120A0 (zh) |
MX (1) | MX2016010177A (zh) |
NZ (1) | NZ723237A (zh) |
PH (1) | PH12016501554A1 (zh) |
RU (1) | RU2016135933A (zh) |
SG (1) | SG11201606439VA (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110267982B (zh) | 2016-10-19 | 2024-02-23 | 斯克利普斯研究所 | 具有人源化靶向部分和/或经过优化的嵌合抗原受体相互作用结构域的嵌合抗原受体效应细胞开关以及其用途 |
CN107164411A (zh) * | 2017-06-29 | 2017-09-15 | 中国农业科学院兰州兽医研究所 | 一种程序性坏死诱导系统的建立方法 |
CN111154807B (zh) * | 2020-01-17 | 2023-03-24 | 山东农业大学 | 一种分泌型的崂山奶山羊乳腺上皮细胞系的构建方法 |
CN113122538A (zh) * | 2021-04-15 | 2021-07-16 | 遵义医科大学附属医院 | 一种靶向敲减Rip3基因表达的shRNA、重组载体及其应用 |
CN113834937B (zh) * | 2021-08-24 | 2022-06-03 | 中日友好医院(中日友好临床医学研究所) | 一组区分特发性炎性肌病的诊断标记物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008104543A3 (en) * | 2007-02-26 | 2008-11-06 | Inst Nat Sante Rech Med | Method for predicting the occurrence of metastasis in breast cancer patients |
CN101932338A (zh) * | 2008-01-31 | 2010-12-29 | 学校法人庆应义墪 | 抗癌剂感受性的判定方法 |
CN103417982A (zh) * | 2012-05-16 | 2013-12-04 | 上海市肿瘤研究所 | 人源性长寿保障基因2在制备提高乳腺癌细胞对抗癌药物的敏感性的药物中的用途 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10013029A1 (de) | 2000-03-17 | 2001-09-20 | Roehm Gmbh | Mehrschichtige Arzneiform für die Colonfreigabe |
US6613753B2 (en) * | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
EP1762575A1 (en) | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
RU2429014C2 (ru) | 2006-03-31 | 2011-09-20 | Массачусетс Инститьют Оф Текнолоджи | Лечение опухолей, экспрессирующих мутантные рецепторы egf |
US20100286058A1 (en) * | 2007-03-09 | 2010-11-11 | Isabella Tai | Assessing Chemotherapy Resistance of Colorectal Tumors by Determining Sparc Hypermethylation |
US20090162434A1 (en) | 2007-12-21 | 2009-06-25 | Disphar International Bv | Mesalazine tablet |
MX2010010021A (es) | 2008-03-12 | 2011-02-15 | Imclone Llc | Anticuepos anti-tyrp1. |
US7622106B1 (en) | 2009-03-06 | 2009-11-24 | Board Of Regents, The University Of Texas System | Necrosis assay |
US20110042247A1 (en) | 2009-06-25 | 2011-02-24 | Chandrasekhar Kocherlakota | Formulations of azacitidine and its derivatives |
WO2011028660A1 (en) * | 2009-09-01 | 2011-03-10 | Trustees Of Dartmouth College | Compositions for inhibiting growth of cancer stem cells |
US20130237445A1 (en) * | 2010-09-14 | 2013-09-12 | The University Of North Carolina At Chapel Hill | Methods and kits for detecting melanoma |
BR112013014195A2 (pt) | 2010-12-09 | 2017-08-15 | Hoffmann La Roche | Método para a identificação de um paciente, composição, uso de bevacizumabe para a preparação de uma composição farmacêutica, método para o tratamento de um distúrbio proliferativo e composição, uso ou método |
CN102319218B (zh) | 2011-09-22 | 2014-10-01 | 贝沃特医药技术(上海)有限公司 | 一种治疗肠道疾病的药物缓控释微粒制剂及其制备方法 |
WO2013123588A1 (en) | 2012-02-22 | 2013-08-29 | Alethia Biotherapeutics Inc. | Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer |
-
2014
- 2014-11-25 JP JP2016568771A patent/JP6464436B2/ja active Active
- 2014-11-25 EP EP14882054.1A patent/EP3103475B1/en active Active
- 2014-11-25 AU AU2014382143A patent/AU2014382143B2/en not_active Ceased
- 2014-11-25 MX MX2016010177A patent/MX2016010177A/es unknown
- 2014-11-25 CA CA2938821A patent/CA2938821A1/en not_active Abandoned
- 2014-11-25 CN CN201480077473.XA patent/CN106132435B/zh active Active
- 2014-11-25 RU RU2016135933A patent/RU2016135933A/ru not_active Application Discontinuation
- 2014-11-25 NZ NZ723237A patent/NZ723237A/en not_active IP Right Cessation
- 2014-11-25 US US15/116,591 patent/US10391115B2/en active Active
- 2014-11-25 SG SG11201606439VA patent/SG11201606439VA/en unknown
-
2016
- 2016-08-04 CL CL2016001965A patent/CL2016001965A1/es unknown
- 2016-08-04 IL IL247120A patent/IL247120A0/en unknown
- 2016-08-05 PH PH12016501554A patent/PH12016501554A1/en unknown
- 2016-12-14 HK HK16114238A patent/HK1225960A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008104543A3 (en) * | 2007-02-26 | 2008-11-06 | Inst Nat Sante Rech Med | Method for predicting the occurrence of metastasis in breast cancer patients |
CN101932338A (zh) * | 2008-01-31 | 2010-12-29 | 学校法人庆应义墪 | 抗癌剂感受性的判定方法 |
CN103417982A (zh) * | 2012-05-16 | 2013-12-04 | 上海市肿瘤研究所 | 人源性长寿保障基因2在制备提高乳腺癌细胞对抗癌药物的敏感性的药物中的用途 |
Also Published As
Publication number | Publication date |
---|---|
NZ723237A (en) | 2018-02-23 |
IL247120A0 (en) | 2016-09-29 |
HK1225960A1 (zh) | 2017-09-22 |
JP6464436B2 (ja) | 2019-02-06 |
CA2938821A1 (en) | 2015-08-13 |
RU2016135933A (ru) | 2018-03-15 |
CL2016001965A1 (es) | 2017-03-17 |
CN106132435A (zh) | 2016-11-16 |
MX2016010177A (es) | 2017-01-09 |
AU2014382143B2 (en) | 2018-02-08 |
RU2016135933A3 (zh) | 2018-03-15 |
US20160346307A1 (en) | 2016-12-01 |
SG11201606439VA (en) | 2016-09-29 |
JP2017511812A (ja) | 2017-04-27 |
US10391115B2 (en) | 2019-08-27 |
EP3103475A1 (en) | 2016-12-14 |
AU2014382143A1 (en) | 2016-09-01 |
EP3103475A4 (en) | 2017-07-12 |
PH12016501554A1 (en) | 2016-09-14 |
EP3103475B1 (en) | 2020-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhou et al. | Effect of microRNA-135a on cell proliferation, migration, invasion, apoptosis and tumor angiogenesis through the IGF-1/PI3K/Akt signaling pathway in non-small cell lung cancer | |
Sun et al. | The function of Piezo1 in colon cancer metastasis and its potential regulatory mechanism | |
Hosono et al. | CXCL8 derived from tumor-associated macrophages and esophageal squamous cell carcinomas contributes to tumor progression by promoting migration and invasion of cancer cells | |
Rong et al. | Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis | |
US9164105B2 (en) | Pancreatic cancer biomarker using the characteristics of pancreatic cancer stem cells, and use thereof | |
Liu et al. | Inhibition of Ca2+‐activated chloride channel ANO1 suppresses ovarian cancer through inactivating PI3K/Akt signaling | |
Wang et al. | Knockdown of HDAC1 expression suppresses invasion and induces apoptosis in glioma cells | |
Pan et al. | Annexin A3 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma | |
CN106132435B (zh) | 筛选通过促进rip3表达增强抗癌药物的敏感性的抗癌辅剂的方法和试剂盒 | |
Li et al. | CHD1L contributes to cisplatin resistance by upregulating the ABCB1–NF-κB axis in human non-small-cell lung cancer | |
Nordentoft et al. | Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer | |
Wen et al. | EphA2 affects the sensitivity of oxaliplatin by inducing EMT in oxaliplatin-resistant gastric cancer cells | |
Yang et al. | miR-128-3p inhibits apoptosis and inflammation in LPS-induced sepsis by targeting TGFBR2 | |
Li et al. | TMEM43 promotes pancreatic cancer progression by stabilizing PRPF3 and regulating RAP2B/ERK axis | |
Huang et al. | Circ_0072995 promotes ovarian cancer progression through regulating miR-122-5p/SLC1A5 axis | |
Kikuchi et al. | Functional analysis of the DEPDC1 oncoantigen in malignant glioma and brain tumor initiating cells | |
Pei et al. | SLC16A1-AS1 enhances radiosensitivity and represses cell proliferation and invasion by regulating the miR-301b-3p/CHD5 axis in hepatocellular carcinoma | |
Hou et al. | Inhibition of protein PMP22 enhances etoposide-induced cell apoptosis by p53 signaling pathway in Gastric Cancer | |
US10921325B2 (en) | Composition for anticancer adjuvant comprising RIP3 expression promoter as active ingredient, method for screening anticancer adjuvant which promotes RIP3 expression and enhances sensitivity of anticancer agent, and method for monitoring sensitivity of anticancer agent | |
Chen et al. | ZNF143 facilitates the growth and migration of glioma cells by regulating KPNA2-mediated Hippo signalling | |
Cai et al. | Krüppel-like factor 17 inhibits urokinase plasminogen activator gene expression to suppress cell invasion through the Src/p38/MAPK signaling pathway in human lung adenocarcinoma | |
KR101721407B1 (ko) | Rip3 발현을 촉진하여 항암제 감수성을 증진시키는 항암 보조제 스크리닝 방법 및 항암제 감수성 모니터링 방법 | |
Stern et al. | Potential role of the bitter taste receptor T2R14 in the prolonged survival and enhanced chemoresponsiveness induced by apigenin | |
JP7012363B2 (ja) | がん患者におけるfstl1阻害剤による治療効果を予測するためのバイオマーカー | |
Xiong et al. | Overexpression of chromodomain helicase DNA binding protein 5 (CHD5) inhibits cell proliferation and induces cell cycle arrest and apoptosis in chronic myeloid leukemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1225960 Country of ref document: HK |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20181206 Address after: Gyeonggi Do, South Korea Applicant after: Ajou University Industry Acade Address before: Seoul, South Kerean Applicant before: Dong Wha Pharm Ind Co., Ltd. (KR) |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1225960 Country of ref document: HK |